Tech Alert: Outcomes of the Permissible ingredients consultation: Valerian, Chelidonium, Chaparral 

The TGA has published outcomes of the consultation on proposed low0negligible risk changes to the Permissible Ingredients Determination, which occurred in August – September 2022.

The outcome of the consultation is largely aligned with CMA’s submission to the consultation, which advocated for a number of changes to reduce the level of impact of the proposal. These changes relate to warning statements for:

 – Valerian

 – Chelidonium

 – Chaparral

The final changes will commence on 1 March 2023, after which new (or newly ‘grouped’) medicines that are released for supply are generally expected to be compliant with new requirements.

For existing medicines, a one-year transition period will be instated to allow sponsors to ensure product compliance, ending on 1 March 2024

LinkedIn
Facebook
Twitter
Email

RECENT ARTICLES

Vale Stephen Myers

It is with great sadness that we learned of the passing of Emeritus Professor Stephen Myers late last week. Stephen was a giant in the

Read More